WO1994027593A1 - Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion - Google Patents
Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion Download PDFInfo
- Publication number
- WO1994027593A1 WO1994027593A1 PCT/US1994/005630 US9405630W WO9427593A1 WO 1994027593 A1 WO1994027593 A1 WO 1994027593A1 US 9405630 W US9405630 W US 9405630W WO 9427593 A1 WO9427593 A1 WO 9427593A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostratin
- pma
- nmole
- dpp
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 116
- 230000009826 neoplastic cell growth Effects 0.000 title claims abstract description 33
- CBDIJHBGVGPIIE-MCDHERAVSA-N 1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-4a,7b,9a-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-,(1ar,1bs,4ar,7as,7br,8r,9as)-5h-cyclopropa(3,4)benz(1,2-e)azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 CBDIJHBGVGPIIE-MCDHERAVSA-N 0.000 title claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 24
- -1 12-deoxyphorbol ester Chemical class 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 3
- 229940049953 phenylacetate Drugs 0.000 claims description 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 abstract description 85
- GZNWHPFWQMQXII-UHFFFAOYSA-N 1-(2-ethylphenyl)pyrrole-2,5-dione Chemical compound CCC1=CC=CC=C1N1C(=O)C=CC1=O GZNWHPFWQMQXII-UHFFFAOYSA-N 0.000 abstract description 70
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 93
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 description 82
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 80
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 79
- 238000011282 treatment Methods 0.000 description 60
- 208000003154 papilloma Diseases 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 31
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 30
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 108090000315 Protein Kinase C Proteins 0.000 description 22
- 102000003923 Protein Kinase C Human genes 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 19
- 206010020718 hyperplasia Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 239000002644 phorbol ester Substances 0.000 description 15
- 150000004633 phorbol derivatives Chemical class 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 208000005623 Carcinogenesis Diseases 0.000 description 13
- 230000036952 cancer formation Effects 0.000 description 13
- 231100000504 carcinogenesis Toxicity 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000717 tumor promoter Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 8
- 229960005520 bryostatin Drugs 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000012190 activator Substances 0.000 description 6
- 238000010562 histological examination Methods 0.000 description 6
- 241000220479 Acacia Species 0.000 description 5
- 108010044467 Isoenzymes Proteins 0.000 description 5
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- MJQUEDHRCUIRLF-YCVQJEHTSA-N bryostatins Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)C([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-YCVQJEHTSA-N 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000000722 protumoral effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000557626 Corvus corax Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 229930004069 diterpene Natural products 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 3
- NQSPTMFCJGKOQJ-UHFFFAOYSA-N 2,2,2-trifluoro-1-(3-fluorophenyl)ethanone Chemical compound FC1=CC=CC(C(=O)C(F)(F)F)=C1 NQSPTMFCJGKOQJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000001307 Myosotis scorpioides Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000670 co-carcinogen Toxicity 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- LMLOFRDITXUVHZ-BPNNYVJBSA-N ac1l3xbq Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CC)C1(C)C LMLOFRDITXUVHZ-BPNNYVJBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 2
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000004715 cellular signal transduction Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036566 epidermal hyperplasia Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HJEHMBCPVHLCOG-UHFFFAOYSA-N 1-ethynyl-4-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(C#C)C=C1 HJEHMBCPVHLCOG-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 208000002931 Cocarcinogenesis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001224046 Pimelea prostrata Species 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FDFRQMKAXPLXFL-UZAJRZOCSA-N ac1l576h Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)C2)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCCCCCCCCCCCC)C1(C)C FDFRQMKAXPLXFL-UZAJRZOCSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000003402 anti-promotion Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003142 cocarcinogen Substances 0.000 description 1
- 230000004760 cocarcinogenesis Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
Definitions
- the present invention relates to the inhibition of neoplasia and tumor promotion, particularly the use of phorbol diterpenes to inhibit neoplasia and tumor promotion.
- the diterpene alcohol phorbol has been disclosed as an antineoplastic agent (U.S. Patent 4,716,179), and the phorbol derivatives phorbol-12,13- diacetate (PDA), phorbol-12,13-dipropionate (PDPr) , phorbol-12,13-dibutyrate (PDBu) , phorbol-12,13-dibenzoate (PDB) , and phorbol 12,13,20-triester (PTA) have been disclosed as inhibiting tumor promotion by the tumor promoter 12-0-tetradecanoylphorbol-13-acetate (TPA) in 7,12-dimethylbenzanthracene (DMBA)-initiated mouse skin (Schmidt et al., "Simple Phorbol Esters as Inhibitors of Tumor Promotion by TPA in Mouse Skin," in Carcino ⁇ enesis and Biological Effects of Tumor Promoters.
- PDA phorbol-12,13- diacetate
- PDPr phorbol-12,
- the present invention provides such inhibitors of neoplasia and tumor promoters, including the potent tumor promoter of the phorbol ester class TPA, which is also known as phorbol 12- myristate 13-acetate (PMA) .
- TPA phorbol 12- myristate 13-acetate
- the present invention provides a method of inhibiting neoplasia and tumor promotion.
- the method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol 13- monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP) .
- a 12-deoxyphorbol 13- monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP) .
- Figures 1A and IB are graphs illustrating the inhibition by prostratin of tumor promotion.
- Figure 1A is a plot of the percent of mice with papillomas versus weeks of treatment
- Figure IB is a plot of the number of papillomas per mouse versus weeks of treatment. The data points are for various groups of mice in a first set of experiments.
- Figures 2A-2D are graphs illustrating the inhibition by prostratin and dPP of tumor promotion.
- Figures 2A and 2C are plots of the percent of mice with papillomas versus weeks of treatment, while Figures 2B and 2D are plots of the number of papillomas per mouse versus weeks of treatment. The data points are for various groups of mice in a second set of experiments.
- Figures 3A and 3B are graphs illustrating the dose- dependent inhibition by prostratin and dPP of tumor promotion.
- Figures 3A and 3B are plots of the number of papillomas per mouse versus pretreatment dose of prostratin and dPP, respectively.
- the data points are for pooled similar groups of mice in the first and second sets of experiments.
- Figures 4A and 4B are graphs illustrating the inhibition by multiple dPP treatments of tumor promotion.
- Figure 4A is a plot of the percent of mice with papillomas versus weeks of treatment
- Figure 4B is a plot of the number of papillomas per mouse versus weeks of treatment.
- the data points are for various groups of mice in third and fourth sets of experiments.
- the present invention is predicated on the surprising discovery that 12-deoxyphorbol 13-monoesters not only are not tumor promoting but are inhibitors of neoplasia and tumor promotion.
- the present invention therefore, provides a method of inhibiting neoplasia and tumor promotion comprising administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol 13-monoester.
- the 12-deoxyphorbol 13- monoester is preferably one in which the ester is selected from the group consisting of formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate, and phenylacetate.
- 12-deoxyphorbol 13- monoester is the 12-deoxyphorbol 13-acetate (prostratin) or 12-deoxyphorbol 13-phenylacetate (dPP) .
- the 12- deoxyphorbol 13-monoester may be administered in any suitable manner, most typically with a pharmaceutically acceptable carrier.
- the 12-deoxyphorbol 13-monoesters exemplified by prostratin and dPP form a new class of protein kinase C (PKC) activators of unique biological activity. Although they bind to and activate PKC, in mouse skin they either fail to induce typical phorbol ester (PMA) effects (e.g., hyperplasia) or induce only partial response (e.g., inflammation) . Furthermore, pretreatment with these agents inhibits a range of PMA induced effects (acute and chronic hyperplasia, inflammation, etc.).
- PMA phorbol ester
- pretreatment with these agents inhibits a range of PMA induced effects (acute and chronic hyperplasia, inflammation, etc.).
- the subject compounds reduce both the average number of papillomas and the tumor incidence in a tumor promotion schedule in CD-I mouse skin, in which each PMA application was preceded by 12- deoxyphorbol monoester pretreatment, thereby demonstrating the in vivo efficacy of the present invention in animals, including humans.
- the highest dose of prostratin used (2.56 ⁇ mol or 1 g/pretreatment) caused a 96% (23-fold) reduction in the average number of papillomas with a decrease of tumor incidence from 97% to 40%.
- the highest dose of dPP used (21.4 nmol or 10 ⁇ g/pretreatment) induced an 86% (7-fold) reduction in the average number of papillomas with a reduction of tumor incidence from 100% to 47%.
- the phorbol esters have been the object of intense research effort, initially driven by the potent neoplasia and tumor promoting activity of these compounds in mouse skin.
- PLC protein kinase C
- a family of serine/threonine kinases involved in cellular signal transduction (Nishizuka, Nature, 308 f 693-698 (1984); Nishizuka, Science. 233. 305-312 (1986); Nishizuka, Nature, 334, 661-665 (1988); and Nishizuka, Science. 258. 607-614 (1992)).
- the phorbol esters function as ultrapotent analogs of sn-l,2-diacylglycerol, the lipophilic second messenger generated through hydrolysis of phosphatidy1inositol 4 , 5-biphosphate and phosphatidylcholine (Blumberg, Cancer Res.. 48. 1-8 (1988)).
- This signalling pathway is of central importance in control of cellular growth and differentiation and is a target of multiple oncogenes (Blumberg, Mol. Carcinog.. 4 . , 339-344 (1991)).
- One strategy for dissecting the complexity of control of the protein kinase C pathway has been to exploit differences among phorbol esters and related natural products in the patterns of biological response which they induce (Blumberg, Mol.
- Prostratin has been identified as the constituent in the Samoan medicinal plant Humolanthus nutans, which is responsible for its activity in a screen for anti-HIV agents (Gustafson et al., J. Med. Chem.. 3_5_, 1978-1986 (1992)). Prostratin had been previously identified as a toxic constitute of Pimelea prostrata (Cashmore et al., Tetrahedron Lett.. 1737-1738 (1976)). It was reported to be 144-fold less potent than PMA for mouse ear reddening and, at a dose 40-fold that of PMA, not to be tumor promoting (Zayed et al., Planta Med.. 34. 65-69 (1984)).
- prostratin In mouse skin, prostratin functioned as a partial agonist, inducing ornithine decarboxylase and myeloperoxidase (a marker of neutrophil granulocyte infiltration) only to 25- 30% of the level induced by PMA (Gustafson et al., J. Med. Chem.. 35, 1978-1986 (1992)). No hyperplasia was observed either in response to single or multiple treatments, and keratin K6, a marker of hyperproliferation, was not induced (Szallasi et al., Cancer Res. f 51. 5355-5360 (1991); Szallasi et al., Carcinogenesis. 13, 2161-2167 (1992)).
- prostratin significantly depended on the pretreatment schedule.
- An optimal schedule was treatment with 256 nmol prostratin 24-48 hrs before PMA application and with 2.56 ⁇ mol prostratin 15 min before PMA application.
- a higher dose of prostratin for the initial treatment was less effective (Szallasi et al., Carcinogenesis. 13. 2161-2167 (1992)).
- dPP is comparably potent to PMA for mouse ear reddening (Hergenhahn et al., J. Cancer Res. Clin. Oncol.. 104. 31-39 (1982)), although it shows markedly different kinetics (Szallasi et al., Cancer Res.. 49. 6052-6057 (1989)).
- dPP behaved, in general, similarly to prostratin, both for induction of acute responses and for inhibition of response to PMA, but with 100-fold greater potency.
- the suppression of PMA induced chronic hyperplasia was incomplete (Szallasi et al., Carcinogenesis. 13. 2161-2167 (1992)) .
- Chronic hyperplasia is considered the best correlate of tumor promoting activity in mouse skin (Sisskin et al., Carcinogenesis. 3., 403-407 (1982); Fischer et al.. Cancer Res.. 49. 6693-6699 (1989)).
- the findings underlying the present invention provide great confidence that the failure to observe promotion by prostratin is not simply a consequence of an inadequate dosage level.
- Earlier findings with bryostatin which unambiguously antagonizes a subset of phorbol ester responses in intact cells (Sako et al.. Cancer Res.. 47. 5445-5450 (1987)), yielded only limited evidence for inhibition of promotion (Hennings et al., Carcinogenesis. 8 . , 1343-1346 (1987); Gschwendt et al. , Carcinogenesis f 9_, 555-562 (1988)).
- the 12-deoxyphorbol 13- monoesters show differentially weak affinity for the secondary site involved in insertion of protein kinase C into the membrane (Kazanietz et al., J. Biol. Chem.. 267. 20878-20886 (1992)).
- prostratin and dPP show selective downregulation of PKC ⁇ S compared to PKC ⁇ , in contrast to PMA. Emerging evidence indicates that different protein kinase C isozymes fulfill different cellular functions.
- protein kinase C isozymes ⁇ and ⁇ reconstitute the secretory response
- protein kinase C isozymes ⁇ and e modulate phosphatidylinositol hydrolysis. While the precise model for the anti-promoting activity of 12-deoxyphorbol 13-monoesters is unknown, at least in concept, differential downregulation of isozymes with distinct biological functions provides a plausible model; however, the present invention is not to be limited with respect to any particular perceived anti-promoting model.
- Anti-cancer agents targeted to the regulatory domain of protein kinase C have proven to be a successful strategy, complementing efforts to obtain selectivity for the catalytic domain.
- the concept that protein kinase C activators are necessarily tumor promoters and, therefore, unsuitable as therapeutic agents is no longer a valid one.
- the 12-deoxyphorbol 13-monoesters employed in the present invention may be used alone or in appropriate association, and also may be used in combination with other pharmaceutically active compounds.
- the active agent may be present in the pharmaceutical composition in any suitable quantity.
- the pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are readily available to the public.
- the present inventive method includes the administration to an animal, particularly a mammal, and most particularly a human, of a therapeutically effective amount of one or more of the aforementioned 12-deoxyphorbol 13-monoesters as an active agent effective in the inhibition of neoplasia and tumor promotion, as well as pharmaceutically acceptable derivatives and salts thereof.
- suitable methods of administering a compound of the present invention to an animal are available, and, although more than one route can be used to administer a particular compound, a particular route can provide a more immediate and more effective reaction than another route.
- Pharmaceutically acceptable excipients are also well-known to those who are skilled in the art, and are readily available. The choice of excipient will be determined in part by the particular compound, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following methods and excipients are merely exemplary and are in no way limiting.
- the pharmaceutically acceptable excipients preferably do not interfere with the action of the active ingredients and do not cause adverse side-effects.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
- Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
- Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- a flavor usually sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- the compounds of the present invention can be made into aerosol formulations to be administered via inhalation.
- aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze- dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- Formulations suitable for topical administration include lozenges comprising the active ingredient in a flavor, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carier; as well as creams, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
- formulations suitable for rectal administration may be presented as suppositories by mixing with a variety of bases such as emulsifying bases or water- soluble bases.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
- the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a prophylactic or therapeutic response in the animal over a reasonable time frame.
- dosage will depend upon a variety of factors including the strength of the particular compound employed, the condition of the animal, the body weight of the animal, as well as the severity and stage of the neoplasia and tumor promotion.
- the compounds employed in the present inventive method will be administered to the surface of tissue, e.g., topically to skin and internally to the gastrointestinal tract, nasal passages, and lung.
- the administered dose will generally need to take into account the surface area of the tissue to be treated.
- the size of the dose will also be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound. Suitable doses and dosage regimens can be determined by comparisons to other anti-neoplasia and anti- tumor compounds known to effect the desired response. Specifically, a suitable dose is that which will result in a concentration of the active agent (typically on the surface of tissue) which is known to effect the desired response. The preferred dosage is the amount which results in maximum inhibition of neoplasia and tumor promotion, without significant side effects. An effective amount of the compounds employed in the present invention is that amount which is sufficient to elicit some inhibition response in neoplasia and tumor promotion in a particular animal.
- the present invention provides for a wide range of the inhibition of neoplasia and tumor promotion, e.g., from little inhibition of neoplasia and tumor promotion to essentially full inhibition of neoplasia and tumor promotion.
- Typical doses include about 1-100,000 nmol prostratin/ml carrier and about 0.1-10,000 nmol dPP/ml carrier, more typically about 10-50,000 nmol prostratin/ml carrier and about 1-5,000 nmol dPP/ml carrier, most typically about 1,000-30,000 nmol prostratin/ml carrier and about 10-3,000 nmol dPP/ml carrier.
- Example 1 This example demonstrates the in vivo efficacy of the present inventive method by illustrating the inhibition by prostratin of neoplasia and tumor promotion in animals.
- DMBA was obtained from Eastman, Rochester, NY.
- PMA, prostratin, and dPP were obtained from LC Services, Woburn, MA. The prostratin was repurified before use. Seven groups of 30 mice each were established (groups 1-7) .
- mice were subjected to a treatment schedule consisting of initiation (day 1) , pretreatment (day 15) , and promotion with two compounds (weeks 3-22; twice/week; 15 minute difference between the treatments with the two compounds in the designated order; beginning with day 17) .
- the initiation involved the topical administration to the mice of either 20 nmol (50 ⁇ g) of dimethylbenzanthracene (DMBA, a known carcinogen) dissolved in 200 ⁇ l of acetone or merely 200 ⁇ l acetone (a carrier material which is not a carcinogen) .
- DMBA dimethylbenzanthracene
- the pretreatment involved administering to the mice either 100 ⁇ l acetone or 256 nmol prostratin.
- the promotion involved the administration of various combinations and concentrations of acetone, PMA, and prostratin to the initiated skin area.
- the DMBA was applied in 200 ⁇ l acetone, while all other treatments were applied in 100 ⁇ l acetone.
- the precise treatment schedule is set forth in Table 1. The employed treatment schedule was based on the most effective protocol inhibiting PMA induced chronic hyperplasia (Szallasi et al.. Cancer Res... 51. 5355-5360 (1991) and Szallasi et al., Carcinogenesis. 13.
- mice were pretreated two days before the first PMA treatment (the beginning of the promotion) and during the promotion period every single PMA treatment was preceded by a corresponding prostratin pretreatment at a 15 min interval.
- mice with papillomas and the number of papillomas per mouse versus the weeks of treatment were plotted as graphs constituting Figures 1A and IB, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 ⁇ l acetone/8.1 nmol PMA (group 2), (O) 2.56 ⁇ mol prostratin/8.1 nmol PMA (group 3), ( ⁇ ) 256 nmol prostratin/8.1 nmol PMA (group 4), and ( ⁇ )
- the percent with papillomas is defined as the percentage of surviving animals bearing one or more papillomas at every second week
- Example 2 This example demonstrates the in vivo efficacy of the present inventive method by illustrating the inhibition by prostratin and dPP of neoplasia and tumor promotion in animals.
- This second set of experiments was carried out in a manner similar to the first set of experiments set out in Example 1, except that thirteen groups of 40 mice (groups 8 and 10-21) and one group of 100 mice (group 9) were established.
- the initiation process and general procedure were the same in the two sets of experiments; however, the pretreatment involved administering to the mice either 100 ⁇ l acetone, 256 nmol prostratin, or 2.14 nmol dPP.
- the promotion involved the administration of various combinations and concentrations of acetone, PMA, prostratin, and dPP to the initiated skin area.
- the precise treatment schedule is set forth in Table 2.
- Example 5 papillomas were counted every second week.
- 7th, 12th, and 22nd week i.e., 5, 10, and 20 weeks after the first PMA treatment
- two mice per group were sacrificed as in Example 1 for histological examinations which are described in Example 5.
- mice with papillomas and the number of papillomas per mouse versus the weeks of treatment with dPP were plotted as graphs constituting Figures 2A and 2B, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 ⁇ l acetone/8.1 nmol PMA (group 9), (O) 21.4 nmol dPP/8.1 nmol PMA (group 11), ( ⁇ ) 2.14 nmol dPP/8.1 nmol PMA (group 12), ( ⁇ ) 214 pmol dPP/8.1 nmol PMA (group 13), (A) 21.4 pmol dPP/8.1 nmol PMA (group 14), and ( ⁇ ) 2.14 pmol dPP/8.1 nmol PMA (group 15) .
- mice with papillomas and the number of papillomas per mouse versus the weeks of treatment with prostratin were plotted as graphs constituting Figures 2C and 2D, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 ⁇ l acetone/8.1 nmol PMA (group 9), (O) 256 nmol prostratin/8.1 nmol PMA (group 16), ( ⁇ ) 25.6 nmol prostratin/8.1 nmol PMA (group 17), ( ⁇ ) 2.56 nmol prostratin/8.1 nmol PMA (group 18), (A) 256 pmol prostratin/8.1 nmol PMA (group (19), and ( ⁇ ) 25.6 pmol prostratin/8.1 nmol PMA (group 20).
- the percent with papillomas is defined as the percentage of surviving animals bearing one or more papillomas at every second week
- Example 3 This example demonstrates and evaluates the dose-dependent nature of prostratin and dPP treatments on the in vivo inhibition of neoplasia and tumor promotion in animals.
- Example 4 This example further confirms the inhibitory effect of dPP on neoplasia and tumor promotion by evaluating different treatment regimens.
- two 12-deoxyphorbol monoester pretreatments were needed for maximal inhibition of acute hyperplasia (Szallasi et al.. Cancer Res. r 51. 5355-5360 (1991); Szallasi et al., Carcinogenesis r 13, 2161-2167 (1992)).
- the first pretreatment preceded the second one by 24-48 hours, and the dose of the first treatment was 10-fold lower than that of the second pretreatment. Since the mechanistic basis for this optimal short term schedule is unknown, several variants for the neoplasia and tumor promotion experiments in Examples 1 and 2 were evaluated.
- Example 5 papillomas were counted every second week.
- 7th, 12th, and 22nd week i.e., 5, 10, and 20 weeks after the first PMA treatment
- two mice per group were sacrificed as in Example 1 for histological examinations which are described in Example 5.
- mice with papillomas and the number of papillomas per mouse versus the weeks of treatment were plotted as graphs constituting Figures 4A and 4B, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 ⁇ l acetone/8.1 nmol PMA twice weekly (group 9), (O) 21.4 nmol dPP/8.1 nmol PMA twice weekly (group 22), ( ⁇ ) 21.4 nmol dPP/16.2 nmol PMA once weekly (group 23), and ( ⁇ ) 100 ⁇ l acetone/16.2 nmol PMA once weekly (group 24) .
- Group 9 (•) is the control for group 22 (O)
- group 24 ( ⁇ ) is the control for group 23 ( ⁇ ) .
- Example 5 This example presents the results of the histological examinations performed on the sacrificed mice of Examples 1, 2, and 4 to assess hyperplasia.
- the set of experiments in Example 1 on the 5th, 10th, and 20th week after the first PMA treatment, two mice per group were sacrificed for histological examinations.
- the dorsal skin of two mice from each group was removed and fixed in either Bouin fixative or 70% ethanol. It was then sectioned and stained with hematoxylin-eosin by American Histolabs, Gaithersburg, MD. Under each set of conditions, two portions of the treated skin were excised per animal, and three sections were prepared from each portion of skin.
- mice per group were sacrificed for histological examinations as in the same manner described above.
- the chronic PMA treatment used for tumor promotion induced very significant hyperplasia in the positive control animals (group 9) .
- group 9 The chronic PMA treatment used for tumor promotion induced very significant hyperplasia in the positive control animals (group 9) .
- group 9 After 7 and 12 weeks, of treatment significant inhibition of hyperplasia was detected in those groups in which the reduction of the average number of papillomas was the most prominent, namely in groups with 256 nmol prostratin or 21.4 nmol dPP pretreatment (groups 11, 16, 22, and 23). No inhibition could be observed in those groups with less significant inhibition of the number of papillomas.
- group 11 16, 22, and 23 the evaluation of the sections became more complicated because of the frequent appearance of papillomas.
- groups of maximal inhibition groups 11, 16, 22, and 23
- those parts of the sections which were far from papillomas or micropapillomas showed clear inhibition of hyperplasia.
Abstract
The present invention provides a method of inhibiting neoplasia and tumor promotion. The method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol ester, particularly a 12-deoxyphorbol 13-monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP).
Description
USE OF 12-DE0XYPH0RB0L 13-MONOESTERS FOR INHIBITING NEOPLASIA AND TUMOR PROMOTION
TECHNICAL FIELD OF THE INVENTION The present invention relates to the inhibition of neoplasia and tumor promotion, particularly the use of phorbol diterpenes to inhibit neoplasia and tumor promotion.
BACKGROUND OF THE INVENTION Many compounds have been identified as carcinogenic agents, particularly neoplasia and tumor promoters. In the study of the mechanism of neoplasia and tumor promotion, phorbol esters have received particular attention and are characterized as extremely potent tumor promotion agents (Blumberg et al., "Specific Receptors for Phorbol Ester Tumor Promoters and Their Involvement in Biological Responses" (Chapter 5) in Mechanisms of Tumor Promotion (Volume III) (Thomas J. Slaga, ed. , CRC Press, Inc., Boca Raton, Florida 1984)). Some phorbol compounds, however, have also been disclosed as useful in the inhibition of neoplasia and tumor promotion. The diterpene alcohol phorbol has been disclosed as an antineoplastic agent (U.S. Patent 4,716,179), and the phorbol derivatives phorbol-12,13- diacetate (PDA), phorbol-12,13-dipropionate (PDPr) , phorbol-12,13-dibutyrate (PDBu) , phorbol-12,13-dibenzoate (PDB) , and phorbol 12,13,20-triester (PTA) have been disclosed as inhibiting tumor promotion by the tumor promoter 12-0-tetradecanoylphorbol-13-acetate (TPA) in 7,12-dimethylbenzanthracene (DMBA)-initiated mouse skin (Schmidt et al., "Simple Phorbol Esters as Inhibitors of Tumor Promotion by TPA in Mouse Skin," in Carcinoαenesis and Biological Effects of Tumor Promoters. 1_, 57-63 (Hecker et al., eds., Raven Press, New York 1982)). The disclosed results regarding the phorbol derivatives, however, have not been replicated, and no inhibition of neoplasia and tumor promotion by TPA by these phorbol derivatives was
found in a different mouse strain (Slaga et al. , "Studies on the Mechanism of Skin Tumor Promotion: Evidence for Several Stages in Promotion," Proc. Natl. Acad. Sci. USA. 72(6) , 3659-3663 (June 1980)). Moreover, the results indicating the inhibition of tumor promotion are inconsistent with the disclosure that PDB and PDBu are tumor promoters (Baird et al.. Cancer Res. f 31. 1074-1079 (1971); Thielman et al., in Fortschritte der Krebsforschunq. 2, 171-179 (Schmidt et al., eds., Schattauer, Stuttgart 1969)) and the general view that the tumor promoting actions of phorbol derivatives are additive and do not cancel each other (Driedger et al., Cancer Res. , 10, 339-346 (1980)).
Thus, there remains a need for effective inhibitors of neoplasia and tumor promotion, particularly such inhibitors which do not have adverse side-effects and can be safely applied to mammals, especially humans. The present invention provides such inhibitors of neoplasia and tumor promoters, including the potent tumor promoter of the phorbol ester class TPA, which is also known as phorbol 12- myristate 13-acetate (PMA) .
These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.
BRIEF SUMMARY OF THE INVENTION The present invention provides a method of inhibiting neoplasia and tumor promotion. The method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol 13- monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP) .
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1A and IB are graphs illustrating the inhibition by prostratin of tumor promotion. Figure 1A is
a plot of the percent of mice with papillomas versus weeks of treatment, while Figure IB is a plot of the number of papillomas per mouse versus weeks of treatment. The data points are for various groups of mice in a first set of experiments.
Figures 2A-2D are graphs illustrating the inhibition by prostratin and dPP of tumor promotion. Figures 2A and 2C are plots of the percent of mice with papillomas versus weeks of treatment, while Figures 2B and 2D are plots of the number of papillomas per mouse versus weeks of treatment. The data points are for various groups of mice in a second set of experiments.
Figures 3A and 3B are graphs illustrating the dose- dependent inhibition by prostratin and dPP of tumor promotion. Figures 3A and 3B are plots of the number of papillomas per mouse versus pretreatment dose of prostratin and dPP, respectively. The data points are for pooled similar groups of mice in the first and second sets of experiments. Figures 4A and 4B are graphs illustrating the inhibition by multiple dPP treatments of tumor promotion. Figure 4A is a plot of the percent of mice with papillomas versus weeks of treatment, while Figure 4B is a plot of the number of papillomas per mouse versus weeks of treatment. The data points are for various groups of mice in third and fourth sets of experiments.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is predicated on the surprising discovery that 12-deoxyphorbol 13-monoesters not only are not tumor promoting but are inhibitors of neoplasia and tumor promotion. The present invention, therefore, provides a method of inhibiting neoplasia and tumor promotion comprising administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol 13-monoester. The 12-deoxyphorbol 13- monoester is preferably one in which the ester is selected
from the group consisting of formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate, and phenylacetate. Most preferably, 12-deoxyphorbol 13- monoester is the 12-deoxyphorbol 13-acetate (prostratin) or 12-deoxyphorbol 13-phenylacetate (dPP) . The 12- deoxyphorbol 13-monoester may be administered in any suitable manner, most typically with a pharmaceutically acceptable carrier.
The 12-deoxyphorbol 13-monoesters exemplified by prostratin and dPP form a new class of protein kinase C (PKC) activators of unique biological activity. Although they bind to and activate PKC, in mouse skin they either fail to induce typical phorbol ester (PMA) effects (e.g., hyperplasia) or induce only partial response (e.g., inflammation) . Furthermore, pretreatment with these agents inhibits a range of PMA induced effects (acute and chronic hyperplasia, inflammation, etc.). The subject compounds reduce both the average number of papillomas and the tumor incidence in a tumor promotion schedule in CD-I mouse skin, in which each PMA application was preceded by 12- deoxyphorbol monoester pretreatment, thereby demonstrating the in vivo efficacy of the present invention in animals, including humans. The highest dose of prostratin used (2.56 μmol or 1 g/pretreatment) caused a 96% (23-fold) reduction in the average number of papillomas with a decrease of tumor incidence from 97% to 40%. The highest dose of dPP used (21.4 nmol or 10 μg/pretreatment) induced an 86% (7-fold) reduction in the average number of papillomas with a reduction of tumor incidence from 100% to 47%. The inhibitory effect was dose dependent, and the ID50 was 11 nmol/pretreatment for prostratin and 0.8 nmol/pretreatment for dPP. Maximal inhibition of tumor promotion was accompanied by a block of epidermal hyperplasia; however, significant inhibition of tumor induction was observed at doses without any apparent effect on the PMA induced hyperplasia.
The Action of Phorbol Esters
The phorbol esters have been the object of intense research effort, initially driven by the potent neoplasia and tumor promoting activity of these compounds in mouse skin. These investigations revealed that the major receptor for the phorbol esters is protein kinase C (PKC) , a family of serine/threonine kinases involved in cellular signal transduction (Nishizuka, Nature, 308f 693-698 (1984); Nishizuka, Science. 233. 305-312 (1986); Nishizuka, Nature, 334, 661-665 (1988); and Nishizuka, Science. 258. 607-614 (1992)). The phorbol esters function as ultrapotent analogs of sn-l,2-diacylglycerol, the lipophilic second messenger generated through hydrolysis of phosphatidy1inositol 4 , 5-biphosphate and phosphatidylcholine (Blumberg, Cancer Res.. 48. 1-8 (1988)). This signalling pathway is of central importance in control of cellular growth and differentiation and is a target of multiple oncogenes (Blumberg, Mol. Carcinog.. 4., 339-344 (1991)). One strategy for dissecting the complexity of control of the protein kinase C pathway has been to exploit differences among phorbol esters and related natural products in the patterns of biological response which they induce (Blumberg, Mol. Carcinog.. 4., 339-344 (1991)). The existence of such differences was an early finding (Hergenhahn et al., J. Cancer Res. Clin. Oncol.. 104. 31-39 (1982) ; Hecker, "Structure-Activity Relationships in Diterpene Esters Irritant and Co-Carcinogenic to Mouse Skin" in Mechanisms of Tumor-Promotion and Carcinogenesis. 11-47 (Slaga et al., eds.. Raven Press, New York 1978)). The most dramatic example of divergent responses is provided by the bryostatins. These compounds, while yet more potent activators of protein kinase C in vitro than the phorbol esters, induce only a subset of responses typical of the phorbol esters and block in a dominant fashion those responses which they themselves do not induce (Blumberg et al., "The Bryostatins, A Family of Protein
Kinase C Activators with Therapeutic Potential" in New Leads and Targets in Drug Research. 273-285 (Krogsgaard- Larsen et al., eds., Alfred Benzon Symposium 33, Munksgaard, Copenhagen 1992)). Recently, a second class of protein kinase C activators has emerged which, like the bryostatins, function at the biological level as partial antagonists, namely the 12-deoxyphorbol 13-monoesters (Zayed et al., Planta Med.. 34. 65-69 (1984)). Whereas 12-deoxyphorbol 13-tetradecanoate was potent both for mouse ear reddening and for tumor promotion, shorter chain derivatives were found to be irritating but not promoting (Zayed et al., Planta Med. , 34f 65-69 (1984)), leading to the conclusion that these biological activities had to be considered as virtually independent (Hecker, "Cocarcinogens from Euphorbiaceae and Thymeleaceae" in Symposium on Pharmacognosy and Phytochemistry, 147-165 (Wagner et al., eds., Springer Verlag 1970)). Initial analysis of short chain 12-deoxyphorbol derivatives in cellular systems, however, failed to reveal unique behavior (Westwick et al., Thromb. Res.. 20, 683-692 (1980); Driedger et al., Cancer Res.. 40, 339-346 (1980)).
Prostratin has been identified as the constituent in the Samoan medicinal plant Humolanthus nutans, which is responsible for its activity in a screen for anti-HIV agents (Gustafson et al., J. Med. Chem.. 3_5_, 1978-1986 (1992)). Prostratin had been previously identified as a toxic constitute of Pimelea prostrata (Cashmore et al., Tetrahedron Lett.. 1737-1738 (1976)). It was reported to be 144-fold less potent than PMA for mouse ear reddening and, at a dose 40-fold that of PMA, not to be tumor promoting (Zayed et al., Planta Med.. 34. 65-69 (1984)). In mouse skin, prostratin functioned as a partial agonist, inducing ornithine decarboxylase and myeloperoxidase (a marker of neutrophil granulocyte infiltration) only to 25- 30% of the level induced by PMA (Gustafson et al., J. Med. Chem.. 35, 1978-1986 (1992)). No hyperplasia was observed
either in response to single or multiple treatments, and keratin K6, a marker of hyperproliferation, was not induced (Szallasi et al., Cancer Res. f 51. 5355-5360 (1991); Szallasi et al., Carcinogenesis. 13, 2161-2167 (1992)). By analogy with the bryostatins, it was assumed that perhaps the partial or complete lack of response reflected suppression of the protein kinase C pathway by prostratin. Indeed, pretreatment with prostratin fully suppressed PMA- induced acute and chronic hyperplasia, induction of ornithine decarboxylase, and keratin K6 expression (Szallasi et al., Cancer Res.. 51. 5355-5360 (1991) and Szallasi et al., Carcinogenesis. 13, 2161-2167 (1992)). Edema and myeloperoxidase were reduced approximately 70% (Szallasi et al., Cancer Res.. 51. 5355-5360 (1991) and Szallasi et al., Carcinogenesis. 13, 2161-2167 (1992)). The effectiveness of prostratin significantly depended on the pretreatment schedule. An optimal schedule was treatment with 256 nmol prostratin 24-48 hrs before PMA application and with 2.56 μmol prostratin 15 min before PMA application. Curiously, a higher dose of prostratin for the initial treatment was less effective (Szallasi et al., Carcinogenesis. 13. 2161-2167 (1992)).
Because prostratin displayed relatively low potency, dPP was also evaluated. dPP is comparably potent to PMA for mouse ear reddening (Hergenhahn et al., J. Cancer Res. Clin. Oncol.. 104. 31-39 (1982)), although it shows markedly different kinetics (Szallasi et al., Cancer Res.. 49. 6052-6057 (1989)). In mouse skin, dPP behaved, in general, similarly to prostratin, both for induction of acute responses and for inhibition of response to PMA, but with 100-fold greater potency. Interestingly, however, the suppression of PMA induced chronic hyperplasia was incomplete (Szallasi et al., Carcinogenesis. 13. 2161-2167 (1992)) . Chronic hyperplasia is considered the best correlate of tumor promoting activity in mouse skin (Sisskin et al., Carcinogenesis. 3., 403-407 (1982); Fischer et al.. Cancer
Res.. 49. 6693-6699 (1989)). Thus, the suppression of hyperplasia by prostratin was arguably a strong predictor that prostratin would be an anti-tumor promoting phorbol ester; however, the suppression of hyperplasia did not reasonably prove such to be the case, particularly since others had reached contrary conclusions regarding the relationship of hyperplasia and tumor effects (Klein- Szanto, "Morphological Evaluation of Tumor Promoter Effects on Mammalian Skin" (Chapter 3) in Mechanisms of Tumor Promotion (Volume II) (Thomas J. Slaga, ed. , CRC Press, Inc., Boca Raton, Florida 1984)).
Inhibition of Neoplasia and Tumor Promotion Mechanism
The discovery that 12-deoxyphorbol 13-monoesters such as prostratin and dPP act as inhibitors of neoplasia and tumor promotion dramatically extends the range of behavior previously described for phorbol ester congeners. Whereas variation in the effectiveness of phorbol derivatives as tumor promoters has achieved acceptance (Hecker, "Structure-Activity Relationships in Diterpene Esters Irritant and Co-Carcinogenic to Mouse Skin" in Mechanisms of Tumor-Promotion and Carcinogenesis. 11-47 (Slaga et al., eds., Raven Press, New York 1978)), prostratin and dPP provide the first persuasive examples for anti-promotion. In addition, the findings underlying the present invention provide great confidence that the failure to observe promotion by prostratin is not simply a consequence of an inadequate dosage level. Earlier findings with bryostatin, which unambiguously antagonizes a subset of phorbol ester responses in intact cells (Sako et al.. Cancer Res.. 47. 5445-5450 (1987)), yielded only limited evidence for inhibition of promotion (Hennings et al., Carcinogenesis. 8., 1343-1346 (1987); Gschwendt et al. , Carcinogenesisf 9_, 555-562 (1988)). The impressive antagonism of PMA promotion in NMRI mice by short-chain phorbol diesters remains the one other example of such antagonism in the literature (Schmidt et al., "Simple Phorbol Esters As
Inhibitors of Tumor Promotion by TPA in Mouse Skin" in Cocarcinogenesis and Biological Effects of Tumor Promoters. 57-63 (Hecker et al., eds.. Raven Press, New York 1982)). Unfortunately, this latter report has not been independently verified, and several of the compounds are either themselves promoting or are not anti-promoting in other mouse strains (Slaga et al., Proc. Natl. Acad. Sci. USA, 72, 3659-3663 (1980); Scribner et al., Europ. J. Cancer. 8., 617-621 (1972); Baird et al., Cancer Res.. 31, 1074-1079 (1971)). An examination of such short-chain substituted phorbol diesters revealed that they do not inhibit hyperplasia, in contrast to the 12-deoxyphorbol 13- monoesters which are the subject of the present inventive method (Szallasi et al., Carcinogenesis. 13, 2161-2167 (1992)).
The mechanism for the antagonism of promotion remains to be determined. In vitro studies were carried out, but they reveal that prostratin and dPP show little selectivity for high affinity binding between protein kinase C isozymes a , β , γ, <5, e, and η. On the other hand, it has been previously reported that protein kinase C shows two functional binding sites for phorbol esters with distinct structure-activity relations (Kazanietz et al., J. Biol. Chem.. 267. 20878-20886 (1992)). The 12-deoxyphorbol 13- monoesters show differentially weak affinity for the secondary site involved in insertion of protein kinase C into the membrane (Kazanietz et al., J. Biol. Chem.. 267. 20878-20886 (1992)). In addition, in several cell types including mouse primary epidermal cells, prostratin and dPP show selective downregulation of PKC<S compared to PKCα, in contrast to PMA. Emerging evidence indicates that different protein kinase C isozymes fulfill different cellular functions. In rat basophilic leukemia RBL-2H3 cells, for example, protein kinase C isozymes β and δ reconstitute the secretory response, whereas protein kinase C isozymes α and e modulate phosphatidylinositol hydrolysis. While the precise model for the anti-promoting
activity of 12-deoxyphorbol 13-monoesters is unknown, at least in concept, differential downregulation of isozymes with distinct biological functions provides a plausible model; however, the present invention is not to be limited with respect to any particular perceived anti-promoting model.
Because of its central role in cellular signal transduction, protein kinase C represents an attractive target for therapeutic intervention. The difficult issue has been how to achieve selectivity. The present invention, together with the earlier work with bryostatin (Blumberg et al., "The Bryostatins, A Family of Protein Kinase C Activators with Therapeutic Potential" in New Leads and Targets in Drug Research. 273-285 (Krogsgaard- Larsen et al., eds., Alfred Benzon Symposium 33, Munksgaard, Copenhagen 1992) , demonstrates that dissection of subpathways of protein kinase C response is possible. Anti-cancer agents targeted to the regulatory domain of protein kinase C have proven to be a successful strategy, complementing efforts to obtain selectivity for the catalytic domain. The concept that protein kinase C activators are necessarily tumor promoters and, therefore, unsuitable as therapeutic agents is no longer a valid one.
Formulations
The 12-deoxyphorbol 13-monoesters employed in the present invention may be used alone or in appropriate association, and also may be used in combination with other pharmaceutically active compounds. The active agent may be present in the pharmaceutical composition in any suitable quantity. The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are readily available to the public.
While the method of the present invention can be practiced in vitro, it has particular usefulness in in vivo applications. As regards these applications, the present inventive method includes the administration to an animal,
particularly a mammal, and most particularly a human, of a therapeutically effective amount of one or more of the aforementioned 12-deoxyphorbol 13-monoesters as an active agent effective in the inhibition of neoplasia and tumor promotion, as well as pharmaceutically acceptable derivatives and salts thereof.
One skilled in the art will appreciate that suitable methods of administering a compound of the present invention to an animal are available, and, although more than one route can be used to administer a particular compound, a particular route can provide a more immediate and more effective reaction than another route. Pharmaceutically acceptable excipients are also well-known to those who are skilled in the art, and are readily available. The choice of excipient will be determined in part by the particular compound, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following methods and excipients are merely exemplary and are in no way limiting. The pharmaceutically acceptable excipients preferably do not interfere with the action of the active ingredients and do not cause adverse side-effects. Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and
pharmacologically compatible excipients. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
The compounds of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.
Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze- dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
Formulations suitable for topical administration include lozenges comprising the active ingredient in a flavor, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia; and
mouthwashes comprising the active ingredient in a suitable liquid carier; as well as creams, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art. Additionally, formulations suitable for rectal administration may be presented as suppositories by mixing with a variety of bases such as emulsifying bases or water- soluble bases. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
Administration The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a prophylactic or therapeutic response in the animal over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors including the strength of the particular compound employed, the condition of the animal, the body weight of the animal, as well as the severity and stage of the neoplasia and tumor promotion. Most typically, the compounds employed in the present inventive method will be administered to the surface of tissue, e.g., topically to skin and internally to the gastrointestinal tract, nasal passages, and lung. Thus, the administered dose will generally need to take into account the surface area of the tissue to be treated. The size of the dose will also be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound. Suitable doses and dosage regimens can be determined by comparisons to other anti-neoplasia and anti- tumor compounds known to effect the desired response. Specifically, a suitable dose is that which will result in a concentration of the active agent (typically on the
surface of tissue) which is known to effect the desired response. The preferred dosage is the amount which results in maximum inhibition of neoplasia and tumor promotion, without significant side effects. An effective amount of the compounds employed in the present invention is that amount which is sufficient to elicit some inhibition response in neoplasia and tumor promotion in a particular animal. In proper doses and with suitable administration of certain compounds, the present invention provides for a wide range of the inhibition of neoplasia and tumor promotion, e.g., from little inhibition of neoplasia and tumor promotion to essentially full inhibition of neoplasia and tumor promotion. Typical doses include about 1-100,000 nmol prostratin/ml carrier and about 0.1-10,000 nmol dPP/ml carrier, more typically about 10-50,000 nmol prostratin/ml carrier and about 1-5,000 nmol dPP/ml carrier, most typically about 1,000-30,000 nmol prostratin/ml carrier and about 10-3,000 nmol dPP/ml carrier.
Examples
The following examples further illustrate the present invention but, of course, should not be construed as in any way limiting its scope.
Example 1 This example demonstrates the in vivo efficacy of the present inventive method by illustrating the inhibition by prostratin of neoplasia and tumor promotion in animals. Female Charles River CD-I mice, 5 weeks of age, were obtained from Charles River Laboratories, Wilmington, MA. The animals were shaved at 6 weeks of age, and mice in the resting phase of the hair cycle were used for tumor promotion experiments. DMBA was obtained from Eastman, Rochester, NY. PMA, prostratin, and dPP were obtained from LC Services, Woburn, MA. The prostratin was repurified before use.
Seven groups of 30 mice each were established (groups 1-7) . The mice were subjected to a treatment schedule consisting of initiation (day 1) , pretreatment (day 15) , and promotion with two compounds (weeks 3-22; twice/week; 15 minute difference between the treatments with the two compounds in the designated order; beginning with day 17) . The initiation involved the topical administration to the mice of either 20 nmol (50 μg) of dimethylbenzanthracene (DMBA, a known carcinogen) dissolved in 200 μl of acetone or merely 200 μl acetone (a carrier material which is not a carcinogen) . The pretreatment involved administering to the mice either 100 μl acetone or 256 nmol prostratin. The promotion involved the administration of various combinations and concentrations of acetone, PMA, and prostratin to the initiated skin area. The DMBA was applied in 200 μl acetone, while all other treatments were applied in 100 μl acetone. The precise treatment schedule is set forth in Table 1. The employed treatment schedule was based on the most effective protocol inhibiting PMA induced chronic hyperplasia (Szallasi et al.. Cancer Res.. 51. 5355-5360 (1991) and Szallasi et al., Carcinogenesis. 13. 2161-2167 (1992)), i.e., all mice were pretreated two days before the first PMA treatment (the beginning of the promotion) and during the promotion period every single PMA treatment was preceded by a corresponding prostratin pretreatment at a 15 min interval.
TABLE 1: Treatment Schedule - First Set of Experiments
Promotion (weeks 3-22, twice/week, 15 min difference between the two
Initiation First Pretreatment treatments in the designated order, oup (day 1) (day 15) from day 17)
1 DMBA (20 nmole) 100 μl acetone 100 μl acetone/100 μl acetone
2 DMBA (20 nmole) 100 μl acetone 100 μl acetone/PMA (8.1 nmole)
3 DMBA (20 nmole) prostratin (256 nmole) prostratin (2.56 μmole)/PMA (8.1 nmole)
4 DMBA (20 nmole) prostratin (256 nmole) prostratin (256 nmole)/PMA (8.1 nmole)
5 DMBA (20 nmole) prostratin (256 nmole) prostratin (25.6 nmole)/PMA (8.1 nmole)
6 DMBA (20 nmole) prostratin (256 nmole) prostratin (2.56 μmole)/100 μl acetone
7 200 μl acetone prostratin (256 nmole) prostratin (2.56 μmole)/100 ml acetone
During this evaluation, papillomas were counted every second week. On the 5th, 10th, and 20th week after the first PMA treatment, two mice per group were sacrificed for histological examinations which are described in Example 5. According to previous results (Szallasi et al.. Cancer Res.. 51. 5355-5360 (1991) and Szallasi et al., Carcinogenesis, 13. 2161-2167 (1992)), multiple prostratin pretreatments of 2.56 μmol were required for complete inhibition of PMA-induced chronic and acute hyperplasia in CD-I mouse skin. The presumed effective doses of prostratin were estimated to be in the same dose range. This proved to be a significant underestimation of the antipromoting potency of prostratin. The percent of mice with papillomas and the number of papillomas per mouse versus the weeks of treatment were plotted as graphs constituting Figures 1A and IB, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 μl acetone/8.1 nmol PMA (group 2), (O) 2.56 μmol prostratin/8.1 nmol PMA (group 3), (■) 256 nmol prostratin/8.1 nmol PMA (group 4), and (□)
25.6 nmol prostratin/8.1 nmol PMA (group 5). The percent with papillomas is defined as the percentage of surviving animals bearing one or more papillomas at every second week
(Figure 1A) , while the number of papillomas per mouse is defined as the total number of papillomas counted divided by the total number of mice surviving every second week (Figure IB) .
The topical application of 8.1 nmol PMA twice/week for 20 weeks induced tumors in 97-100% of the experimental animals by the 20th week (Figure 1A; group 2) . In the positive control group (group 2) , the maximum of the average number of papillomas was 16.5/mouse (after 28 weeks of treatment). Prostratin (2.56 μmol/treatment; twice/week; for 20 weeks) showed neither complete carcinogenic nor tumor promoting activity, i.e., no tumors appeared in any of the groups (groups 6 and 7) with the
aforesaid treatment schedule whether they had been initiated with 20 nmol DMBA or not.
These results clearly demonstrate the significant inhibiting effect of prostratin on neoplasia and tumor promotion.
Example 2 This example demonstrates the in vivo efficacy of the present inventive method by illustrating the inhibition by prostratin and dPP of neoplasia and tumor promotion in animals.
This second set of experiments was carried out in a manner similar to the first set of experiments set out in Example 1, except that thirteen groups of 40 mice (groups 8 and 10-21) and one group of 100 mice (group 9) were established. The initiation process and general procedure were the same in the two sets of experiments; however, the pretreatment involved administering to the mice either 100 μl acetone, 256 nmol prostratin, or 2.14 nmol dPP. The promotion involved the administration of various combinations and concentrations of acetone, PMA, prostratin, and dPP to the initiated skin area. The precise treatment schedule is set forth in Table 2.
TABLE 2: Treatment Schedule - Second Set of Experiments
Promotion (weeks 3-22, twice/week, 15 min difference between the two
Initiation First Pretreatment treatments in the designated order, roup (day 1) (day 15) from day 17)
8 DMBA (20 nmole) 100 μl acetone 100 μl acetone/100 μl acetone
9 DMBA (20 nmole) 100 μl acetone 100 μl acetone/PMA (8.1 nmole)
10 DMBA (20 nmole) dPP (2.14 nmole) dPP (21.4 nmole)/100 μl acetone)
11 DMBA (20 nmole) dPP (2.14 nmole) dPP (21.4 nmole)/PMA (8.1 nmole)
12 DMBA (20 nmole) dPP (2.14 nmole) dPP (2.14 nmole)/PMA (8.1 nmole)
13 DMBA (20 nmole) dPP (2.14 nmole) dPP (214 pmole)/PMA 8.1 nmole)
14 DMBA (20 nmole) dPP (2.14 nmole) dPP (21.4 pmole)/PMA (8.1 nmole)
15 DMBA (20 nmole) dPP (2.14 nmole) dPP (2.14 pmole)/PMA (8.1 nmole)
16 DMBA (20 nmole) prostratin (256 nmole) prostratin (256 nmole)/PMA (8.1 nmole)
17 DMBA (20 nmole) prostratin (256 nmole) prostratin (25.6 nmole)/PMA (8.1 nmole)
18 DMBA (20 nmole) prostratin (256 nmole) prostratin (2.56 nmole)/PMA (8.1 nmole)
19 DMBA (20 nmole) prostratin (256 nmole) prostratin (256 pmole)/PMA (8.1 nmole)
20 DMBA (20 nmole) prostratin (256 nmole) prostratin (25.6 pmole)/PMA (8.1 nmole)
21 100 μl acetone dPP (2.14 nmole) dPP (21.4 nmole)/100 μl acetone
During this evaluation, papillomas were counted every second week. On the 7th, 12th, and 22nd week (i.e., 5, 10, and 20 weeks after the first PMA treatment) , two mice per group were sacrificed as in Example 1 for histological examinations which are described in Example 5.
The percent of mice with papillomas and the number of papillomas per mouse versus the weeks of treatment with dPP were plotted as graphs constituting Figures 2A and 2B, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 μl acetone/8.1 nmol PMA (group 9), (O) 21.4 nmol dPP/8.1 nmol PMA (group 11), (■) 2.14 nmol dPP/8.1 nmol PMA (group 12), (□) 214 pmol dPP/8.1 nmol PMA (group 13), (A) 21.4 pmol dPP/8.1 nmol PMA (group 14), and (Δ) 2.14 pmol dPP/8.1 nmol PMA (group 15) . The percent of mice with papillomas and the number of papillomas per mouse versus the weeks of treatment with prostratin were plotted as graphs constituting Figures 2C and 2D, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 μl acetone/8.1 nmol PMA (group 9), (O) 256 nmol prostratin/8.1 nmol PMA (group 16), (■) 25.6 nmol prostratin/8.1 nmol PMA (group 17), (□) 2.56 nmol prostratin/8.1 nmol PMA (group 18), (A) 256 pmol prostratin/8.1 nmol PMA (group (19), and (Δ) 25.6 pmol prostratin/8.1 nmol PMA (group 20). The percent with papillomas is defined as the percentage of surviving animals bearing one or more papillomas at every second week
(Figures 2A and 2C) , while the number of papillomas per mouse is defined as the total number of papillomas counted divided by the total number of mice surviving every second week (Figures 2B and 2D) .
The topical administration of 8.1 nmol PMA twice/week for 20 weeks induced tumors in 97-100% of the experimental animals by the 20th week (Figures 2A and 2C; group 9) . In the positive control group (group 9) , the maximum of the average number of papillomas was 13.9/mouse (after 26 weeks
of treatment) . In the manner observed for prostratin in Example 1, dPP (21.4 nmol/treatment; twice/week; for 20 weeks) showed neither complete carcinogenic nor tumor promoting activity, i.e., no tumors appeared in any of the groups (groups 10 and 21) with the aforesaid treatment schedule whether they had been initiated with 20 nmol DMBA or not.
These results confirm the significant inhibiting effect of prostratin on neoplasia and tumor promotion and, further, clearly demonstrate the significant inhibiting effect of dPP on neoplasia and tumor promotion.
Example 3 This example demonstrates and evaluates the dose- dependent nature of prostratin and dPP treatments on the in vivo inhibition of neoplasia and tumor promotion in animals.
When PMA application was preceded by pretreatment with different doses of either prostratin or dPP in Examples 1 and 2, both the average number of papillomas and the tumor incidence were reduced in a dose-dependent manner. The highest dose of prostratin pretreatment (2.56 μmol/treatment) reduced the average number of papillomas 96% (23-fold) , and reduced in incidence of tumor from 97% to 40%, relative to the positive control group (compare groups 2 and 3 in Figures 1A and IB). A dose of 21.4 nmol dPP/treatment reduced the average number of papillomas 86% (7-fold) with a decrease in the tumor incidence from 97% to 47% relative to the positive control group (compare groups 9 and 11 in Figures 2A and 2B) .
The data obtained in Examples l and 2 were converted into dose response curves at week 26, when all groups reached a plateau in the level of both tumor incidence and average number of papillomas. The data was separately plotted as the average number of papillomas per mouse versus dose of pretreatment for both prostratin and dPP in
Figures 3A and 3B, respectively. Since the results obtained from groups of identical (prostratin) treatments in the first and second set of experiments in Examples 1 and 2 were very similar, the data for these treatments were pooled in determining the dose response curve of the prostratin treated groups plotted in Figure 3A, wherein the symbol • corresponds to the data from the first set of experiments in Example 1 and the symbol ■ corresponds to the data from the second set of experiments in Example 2. Since dPP was not administered in the first set of experiments in Example 1, and only in the second set of experiments in Example 2, there was no pooling of the dPP treatment data plotted in Figure 3B. The inhibitory effect of both prostratin and dPP was dose-dependent. The ID50 was 11 nmol/pretreatment for prostratin (Figure 3A) , and the ID50 was 0.8 nmol/pretreat ent for dPP (Figure 3B) . Although maximal inhibition of tumor promotion was accompanied by a block of epidermal hyperplasia, significant inhibition of tumor induction was observed at doses without any apparent effect on the PMA-induced hyperplasia.
The analysis of the data demonstrates the dose- dependency of treatments with 12-deoxyphorbol 13-monoesters in the present inventive method.
Example 4 This example further confirms the inhibitory effect of dPP on neoplasia and tumor promotion by evaluating different treatment regimens. According to previous experiments, two 12-deoxyphorbol monoester pretreatments were needed for maximal inhibition of acute hyperplasia (Szallasi et al.. Cancer Res. r 51. 5355-5360 (1991); Szallasi et al., Carcinogenesis r 13, 2161-2167 (1992)). In the optimal protocol, the first pretreatment preceded the second one by 24-48 hours, and the dose of the first treatment was 10-fold lower than that
of the second pretreatment. Since the mechanistic basis for this optimal short term schedule is unknown, several variants for the neoplasia and tumor promotion experiments in Examples 1 and 2 were evaluated. The underlying concept was that the effect of the initial low dose of 12-deoxyphorbol might be lost as the duration of the experiment was extended using the procedures set out in Examples 1 and 2. For an additional group of 40 mice (group 22) , the schedule included a first, low dose dPP pretreatment (2.14 nmol/treatment) every week, but otherwise the treatment pattern was the same as in Example 2. In two additional groups (groups 23 and 24), a single, 2-fold increased dose (16.2 nmol/treatment) of PMA treatment/week was used for promotion. Every PMA treatment was preceded by a lower dose dPP pretreatment (2.14 nmol/treatment) at a 48 h interval and a higher dose dPP pretreatment (21.4 nmol/treatment) at a 15 min interval. This latter protocol allowed a larger interval between the treatment with PMA and the subsequent low dose treatment with dPP. The precise treatment schedules are set forth in Tables 3 and 4.
TABLE 3: Treatment Schedule - Third Set of Experiments
Promotion (Every Friday and Monday,
Pretreatment (Every weeks 3-22, 15 min difference between Thursday, week 3-22) the two treatments in the designated
Group Initiation (from day 15) order)
22 DMBA (20 nmole) dPP (2.14 nmole) dPP (21.4 nmole) /PMA (8.1 nmole)
TABLE 4: Treatment Schedule - Fourth Set of Experiments
Promotion (Every Friday and Monday,
Pretreatment (Every weeks 3-22, 15 min difference between Thursday, week 3-22) the two treatments in the designated
Group Initiation (from day 15) order) 1V
23 DMBA (20 nmole) dPP (2.14 nmole) dPP (21.4 nmole/PMA (16.2 nmole)
24 DMBA (20 nmole) 100 μl acetone 100 μl acetone/PMA (16.2 nmole)
During this evaluation, papillomas were counted every second week. On the 7th, 12th, and 22nd week (i.e., 5, 10, and 20 weeks after the first PMA treatment) , two mice per group were sacrificed as in Example 1 for histological examinations which are described in Example 5.
The percent of mice with papillomas and the number of papillomas per mouse versus the weeks of treatment were plotted as graphs constituting Figures 4A and 4B, respectively, for the groups of mice treated twice/week at 15 min intervals with the following doses: (•) 100 μl acetone/8.1 nmol PMA twice weekly (group 9), (O) 21.4 nmol dPP/8.1 nmol PMA twice weekly (group 22), (□) 21.4 nmol dPP/16.2 nmol PMA once weekly (group 23), and (■) 100 μl acetone/16.2 nmol PMA once weekly (group 24) . Group 9 (•) is the control for group 22 (O) , while group 24 (■) is the control for group 23 (π) .
As illustrated in Figure 4, the variation of the schedule did not appreciably altered the inhibitory potency of the dPP pretreatments.
Example 5 This example presents the results of the histological examinations performed on the sacrificed mice of Examples 1, 2, and 4 to assess hyperplasia. As regards the set of experiments in Example 1, on the 5th, 10th, and 20th week after the first PMA treatment, two mice per group were sacrificed for histological examinations. The dorsal skin of two mice from each group was removed and fixed in either Bouin fixative or 70% ethanol. It was then sectioned and stained with hematoxylin-eosin by American Histolabs, Gaithersburg, MD. Under each set of conditions, two portions of the treated skin were excised per animal, and three sections were prepared from each portion of skin. As regards the sets of experiments in Examples 2 and 4, on the 7th, 12th, and 22nd week (i.e., 5, 10, and 20
weeks after the first PMA treatment) , two mice per group were sacrificed for histological examinations as in the same manner described above.
The chronic PMA treatment used for tumor promotion induced very significant hyperplasia in the positive control animals (group 9) . After 7 and 12 weeks, of treatment significant inhibition of hyperplasia was detected in those groups in which the reduction of the average number of papillomas was the most prominent, namely in groups with 256 nmol prostratin or 21.4 nmol dPP pretreatment (groups 11, 16, 22, and 23). No inhibition could be observed in those groups with less significant inhibition of the number of papillomas. After 22 weeks of treatment, the evaluation of the sections became more complicated because of the frequent appearance of papillomas. However, in the above mentioned groups of maximal inhibition (groups 11, 16, 22, and 23), those parts of the sections which were far from papillomas or micropapillomas showed clear inhibition of hyperplasia.
All of the references cited herein (including publications, patents, patent applications, and the like) are hereby incorporated in their entireties by reference. While this invention has been described with an emphasis upon a preferred embodiment, it will be obvious to those of ordinary skill in the art that variations of the preferred products and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.
Claims
1. A method of inhibiting neoplasia and tumor promotion comprising administering to a mammal in need thereof an effective amount of a 12-deoxyphorbol 13- monoester.
2. The method of claim 1, wherein said ester is selected from the group consisting of formate, acetate, propionate, butyrate, pentanoate, hexanoate, benzoate, and phenylacetate.
3. The method of claim 2, wherein said ester is an acetate.
4. The method of claim 3, wherein said ester is a phenylacetate.
5. The method of claim 1, wherein said 12- deoxyphorbol ester is administered with a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70411/94A AU7041194A (en) | 1993-05-20 | 1994-05-19 | Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US064,251 | 1993-05-20 | ||
US08/064,251 US5405875A (en) | 1991-04-08 | 1993-05-20 | Method of inhibiting neoplasia and tumor promotion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994027593A1 true WO1994027593A1 (en) | 1994-12-08 |
Family
ID=22054619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/005630 WO1994027593A1 (en) | 1993-05-20 | 1994-05-19 | Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion |
Country Status (3)
Country | Link |
---|---|
US (1) | US5405875A (en) |
AU (1) | AU7041194A (en) |
WO (1) | WO1994027593A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022103B2 (en) | 2005-07-13 | 2011-09-20 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067632B2 (en) * | 2007-07-26 | 2011-11-29 | The Board Of Trustees Of The Leland Stanford Junior University | Process to produce prostratin and structural or functional analogs thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017064A2 (en) * | 1991-04-08 | 1992-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of protein kinase c function |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2902506A1 (en) * | 1979-01-23 | 1980-07-24 | Deutsches Krebsforsch | USE OF DITERPENAL ALCOHOLS AND DERIVATIVES THEREOF AS AN ANTINEOPLASTIC AGENT, OR ONLY LITTLE IRRITATING AND / OR PROMOVING |
US5021450A (en) * | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
-
1993
- 1993-05-20 US US08/064,251 patent/US5405875A/en not_active Expired - Lifetime
-
1994
- 1994-05-19 AU AU70411/94A patent/AU7041194A/en not_active Abandoned
- 1994-05-19 WO PCT/US1994/005630 patent/WO1994027593A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992017064A2 (en) * | 1991-04-08 | 1992-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of protein kinase c function |
Non-Patent Citations (4)
Title |
---|
OGURA, M. ET AL: "POTENTIAL ANTICANCER AGENTS VIII. CONSTITUENTS OF BALIOSPERMUM MONTANUM", PLANTA MEDICA, vol. 33, no. 2, 1978, pages 128 - 143 * |
SZALLASI, Z. ET AL: "NON-PROMOTING 12-DEOXYPHORBOL 13-ESTERS AS POTENT INHIBITORS OF PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED ACUTE AND CHRONIC BIOLOGICAL RESPONSES IN CD-1 MOUSE SKIN", CARCINOGENESIS, vol. 13, no. 11, November 1992 (1992-11-01), pages 2161 - 2167 * |
SZALLASI, Z. ET AL: "NONPROMOTING 12-DEOXYPHORBOL 13-ESTERS INHIBIT PHORBOL 12-MYRISTATE 13-ACETATE INDUCED TUMOR PROMOTION IN CD-1 MOUSE SKIN", CANCER RESEARCH, vol. 53, no. 11, 1 June 1993 (1993-06-01), pages 2507 - 2512 * |
SZALLASI, Z. ET AL: "PROSTRATIN, A NONPROMOTING PHORBOL ESTER, INHIBITS INDUCTION BY PHORBOL 12-MYRISTATE 13-ACETATE OF ORNITHINE DECARBOXYLASE, EDEMA AND HYPERPLASIA IN CD-1 MOUSE-SKIN", CANCER RESEARCH, vol. 51, no. 19, 1991, pages 5087 - 5448 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8022103B2 (en) | 2005-07-13 | 2011-09-20 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
US8431612B2 (en) | 2005-07-13 | 2013-04-30 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
Also Published As
Publication number | Publication date |
---|---|
US5405875A (en) | 1995-04-11 |
AU7041194A (en) | 1994-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Szallasi et al. | Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin | |
CA2380072C (en) | Nicotine in therapeutic angiogenesis and vasculogenesis | |
US5457130A (en) | Eicosapentaenoic acid used to treat cachexia | |
EP0469075B1 (en) | Use of lipoxin a 4? and its derivatives as antagonists for slow-reacting substances of anaphylaxis | |
US20010051184A1 (en) | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases | |
EP1207879B1 (en) | Nicotine receptor agonists in stem cell and progenitor cell recruitment | |
EP0783474B1 (en) | Compounds for the suppression of hiv tat transactivation | |
JP2015508065A (en) | Fatty acids as anti-inflammatory drugs | |
US4990537A (en) | Anti influenza agent | |
US6008188A (en) | Cytokine potentiator and pharmaceutical formulation for cytokine administration | |
US5420162A (en) | Phorbol ester pharmaceutical compositions and their use for treating inflammation | |
US5190978A (en) | Carcinostatic compositions and methods | |
US5405875A (en) | Method of inhibiting neoplasia and tumor promotion | |
JPH08511006A (en) | Stable copper (▲ I ▼) complex and method relating thereto | |
WO1996039144A1 (en) | Stable copper(i) complexes as active therapeutic substances | |
JPS58206524A (en) | Antitumor agent | |
US20040028756A1 (en) | Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | |
KR101151701B1 (en) | Composition for Treating Atopic Dermatitis Comprising Hirsutanonol as an Active Ingredient | |
Jung et al. | Effect of prostaglandin on the composition of chinchilla middle ear effusion | |
JPH07196490A (en) | Tumor metastasis inhibitor | |
Satoh et al. | Inhibition of Na+, K+-ATPase by the extract of Stephania cephararantha Hayata and bisbenzylisoquinoline alkaloid cycleanine, a major constituent | |
JP3246683B2 (en) | Cell growth promoting substance and composition containing the same | |
WO2006034495A2 (en) | Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects | |
Pieper et al. | Variable efficacy of N6-(1-iminoethyl)-L-lysine in acute cardiac transplant rejection | |
JP2820458B2 (en) | Anticancer agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |